anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A cosmetic composition and method is herein described for sunless tanning to impart a glow/shiny effect on skin. The composition includes a sunless tanning agent and coated beads incorporating tan colored pigment. A colorant which imparts a color other than tan to the beads is distributed within the coating. The cosmetic composition provides to the skin an immediate tan via the disintegrated beads. Sunless tanning agent acts more slowly and eventually will replace the pigment effect. The coating with colorant prevents the formula undesirably from appearing tan. Instead a color such as white renders the formula more aesthetically pleasing and more in line with the visuals paradigm of a moisturizer rather than a foundation.
PURPOSE:To obtain a film-forming cosmetic giving a coating film having improved durability on skin and affording durable makeup, by adding a specific amount of an N-acyllysine to a cosmetic base containing specific amounts of a water-soluble polymeric substance and water and specifying the viscosity of the mixture. CONSTITUTION:The objective film-forming cosmetic has a viscosity of >=3,000 cps and contains (A) one or more N-acyllysines selected from the compound of formula (R1 and R2 are H or 8-22C acyl; at least one of which is acyl) (preferably N-lauroyllysine, etc.), (B) one or more water-soluble polymeric substances selected from carboxyvinyl polymer, etc., and (C) water or water- containing ethanol. The amounts of the components A, B and C in the whole cosmetic composition are 0.01-5wt%, 0.05-20wt% and 50-99wt%, respectively. Since the cosmetic contains water as a base, it gives refreshing feeling to the skin. The makeup lasts long because the formed film has high affinity with the skin and keeps the hydrophobic property over a long period.
BACKGROUND: To date, only two studies have compared the outcomes of patients with liver-limited BRAF V600E-mutated colorectal liver metastases (CRLMs) managed with resection versus systemic therapy alone, and these have reported contradictory findings.
METHODS: In this observational, international, multicentre study, patients with liver-limited BRAF V600E-mutated CRLMs treated with resection or systemic therapy alone were identified from institutional databases. Patterns of recurrence/progression and overall survival were compared using multivariable analyses of the entire cohort and a propensity score-matched cohort.
RESULTS: Of 170 patients included, 119 underwent hepatectomy and 51 received systemic treatment. Surgically treated patients had a more favourable pattern of recurrence with most recurrences limited to a single site, whereas diffuse progression was more common among patients who received systemic treatment (19 versus 44%; P = 0.002). Surgically treated patients had longer median overall survival (35 versus 20 months; P < 0.001). Hepatectomy was independently associated with better OS than systemic treatment alone (HR 0.37, 95% c.i. 0.21 to 0.65). In the propensity score-matched cohort, surgically treated patients had longer median overall survival (28 versus 20 months; P < 0.001); hepatectomy was independently associated with better overall survival (HR 0.47, 0.25 to 0.88).
CONCLUSION: BRAF V600E mutation should not be considered a contraindication to surgery for patients with resectable, liver-only CRLMs.
Primary liver cancer is the fourth common malignant tumor and the second cause of death in China, which seriously threatens the life and health of Chinese people. Hepatocellular carcinoma accounts for 75% to 85% of primary liver cancer and is considered the leading cause of death in patients with cirrhosis, and its incidence is expected to continue to increase.

At present, the main treatment methods of liver cancer are surgical resection, liver transplantation, interventional therapy, etc., HCC patients are often advanced in initial diagnosis, coupled with cirrhosis, liver function intolerance and other factors, only about 15% of patients can receive surgical resection. Transcatheter arterial chemoembolization (TACE) has been applied in hepatocellular carcinoma for more than 40 years. TACE treatment can be divided into conventional TACE and Drug-eluting beads-transarterial chemoembolization (DEB-TACE) according to different embolic agents. DEB-TACE refers to the embolization therapy based on drug-eluting microspheres loaded with chemotherapy drugs, which can embolize the blood supplying artery of liver cancer to cause tumor ischemia and necrosis. At the same time, as a carrier of chemotherapy drugs, DEB-TACE has the advantage of continuously and steadily releasing drugs, so that the local tumor can reach a higher required concentration. Elaboration transcatheter arterial chemoembolization (E-TACE) is the elaboration transcatheter arterial branch selection of the tumor and the refined embolization is carried out by using uniform drug-loaded microsphere.

Although there have been a large number of randomized controlled studies on TACE treatment of HCC, due to the clear inclusion or exclusion criteria of randomized controlled studies. The results of the studies are different from the real diagnosis and treatment environment due to the limitations of treatment programs. This difference is called the efficacy effectiveness gap (EEG). In addition, the 2022 edition of China Liver Cancer Standard Diagnosis and Treatment Quality Control Indicators and 2022 edition of Primary Liver Cancer Diagnosis and Treatment Guidelines point out that TACE treatment for liver cancer needs to be standardized and refined, to reduce the heterogeneity of tumors leading to differences in TACE efficacy, and ultimately improve the survival rate and survival habits of liver cancer patients. There are currently no real-world studies on the efficacy and safety of E-TACE in the treatment of hepatocellular carcinoma. Therefore, this study intends to conduct a real-world study to evaluate the short-term efficacy and safety of E-TACE in the treatment of hepatocellular carcinoma.
Lung restrictive disorder is one of the reasons that induce chronic fatigue in COVID-19 (Corona Virus Disease-19) survivors. It also gives a significant effect on cardiovascular patients who are in the second phase of cardiac rehabilitation. Breathing exercise and chest mobilization are proven to increase lung functional capacity in Covid-19 survivors. On the other hand, there is still no research that shows the effectiveness of Breathing exercises and chest mobilization in Covid-19 survivors who are suffering from cardiovascular problems.

Patients in National Cardiac Center Hospital, Jakarta, with a history of Covid-19 and have cardiovascular disease are recruited. They will undergo pre and post-exercise examinations such as blood sampling, do 6 minutes walking test, Peak Cough Flow and Peak Flow Rate test, measuring the chest dimension, treadmill, and answer the European Quality of Life Five Dimension (EQ-5D) questions. With randomization, patients will be determined to treatment or control group. They will be prepared about what exercises should they do at home. Subjects will be supervised digitally and regularly through Zoom meetings. Exercises will be done for 3 months.
Participants will receive placebo titrations across 6 weeks. Note that this is a crossover design, so patients will move across phases.
The present invention relates to the stratification and treatment of patients suffering of cancer. Due to the fact that anti-PD1 therapy targets lymphocytes and the efficiency of anti-cancer therapy is measured by the impact on the tumor cells, the inventors postulated that studying the molecular mechanisms of resistance of anti-PD1 therapy should take into consideration existing intercellular communication between lymphocytes and tumor cells. As exosomes are the carriers for the intercellular transfer of the miRNA responsible of chemoresistance, they herein investigated whether exposure of T cells to anti-PD1 therapy might promote the expression of exosomal miRNA (exomiR) causing the chemoresistance of cancer cells. Surprisingly, they found that anti-PD1 exposure of T-cell promotes an enrichment of exosomal miRNA-4315. They also noted that exosomal miRNA-4315 induced a phenomenon of apopto-resistance to conventional chemotherapies in cancer cells receiving exosomal miRNA-4315. At molecular level, they discern that the apopto-resistance phenomenon was associated with the miRNA-4315-mediated down-regulation of Bim, a pro-apoptotic protein. In cellular and mice models, they observed that the BH3 mimetic agent ABT263 circumvented this resistance. Thus, the invention relates to methods of stratification using exosomal miRNA-4315 and method of treatment of patients suffering of cancer using BH3 mimetic agent.
Based on nucleoside analogue (NUCs), carvedilol will added to the patients. Carvedilol is started at a dose of 6.25 mg once daily. After 1 week, this will increased to a dose of 12.5 mg once daily. Target dose of 12.5 mg once daily will be maintained if systolic blood pressure does not fall below 90 mm Hg and HR 50 beats per minute.
DITROPAN XL® (oxybutynin chloride) is an antispasmodic, anticholinergic agent. Each DITROPAN XL® Extended Release Tablet contains 5 mg, 10 mg, or 15 mg of oxybutynin chloride USP, formulated as a once-a-day controlled-release tablet for oral administration. Oxybutynin chloride is administered as a racemate of R- and S-enantiomers.

Chemically, oxybutynin chloride is d,l (racemic) 4-diethylamino-2-butynyl phenylcyclohexylglycolate hydrochloride. The empirical formula of oxybutynin chloride is C22H31NO3•HCl.

Its structural formula is:

Oxybutynin chloride is a white crystalline solid with a molecular weight of 393.9. It is readily soluble in water and acids, but relatively insoluble in alkalis.

DITROPAN XL® also contains the following inert ingredients: cellulose acetate, hypromellose, lactose, magnesium stearate, polyethylene glycol, polyethylene oxide, synthetic iron oxides, titanium dioxide, polysorbate 80, sodium chloride, and butylated hydroxytoluene.
PURPOSE:The titled substance, containing hemicellulose obtained by the extraction from wheat bran or a residue after removing starch, protein, etc. from the wheat bran on the alklaine side as a principal component, and useful as a material for health food and drink, medicine, etc. CONSTITUTION:An inhibitory substance for rise in blood serumal cholesterol containing hemicellulsoe obtained by the extraction of wheat bran (peridermal part in an amount of about 10% of wheat grains, and separated by the grinding step of the wheat flour milling) or a residue after removing impurities, e.g. starch, protien, lipid or inorganic materials, from the wheat bran on the alkaline side as a principal component. The substance consists of about 90% or  more hemicellulose and a little lignin, cellulose, ash, etc. and exhibits the inhibitory action on the rise in the blood serumal cholesterol equal to or higher  than that of the dietary fibers in an amount of (1/50) or less thereof.
African Americans (AA) have the greatest burden of hypertension and elucidating the pathogenesis of this racial disparity is important for amending treatment strategies. Gut microbial dysbiosis has been linked to hypertension and has been characterized as low microbial composition of short chain fatty acid (SCFA) producing microbes. Reduced gut SCFA production has been observed in AA with disease, such as glucose intolerance and vitamin deficiency, and may be related to the pathogenesis of hypertension in this group. Preliminary data show that aerobic exercise improves the gut microbial profile and increases SCFA production in animal models and humans. Additional preliminary data show that the SCFA butyrate attenuates dysfunction in AA endothelial cells suggesting a role for SCFA in endothelial/vascular function. The proposed studies have been constructed to fill a critical void in our understanding of the pathogenesis of hypertension in AA involving the gut microbiome. The investigators hypothesize that lower SCFA production is associated with blood pressure in AA and exercise will be effective in reducing blood pressure by coupling improvements in gut microbial health (↑SCFA production) and vascular health. The proposed research will: 1) quantify the relationship between gut dysbiosis (reduced gut and circulating SCFA) and blood pressure in AA with hypertension and 2) quantify the impact of aerobic exercise training on gut microbial community structure, identify adaptable SCFA microbes related to blood pressure, blood concentrations of SCFA, and blood pressure in AA. The research will provide novel insight into the pathogenesis of hypertension, particularly in the health disparate AA population, and will facilitate the development of future mechanistic studies to advance the clinical communities understanding of the "gut-vascular axis" concerning endothelial function and vascular disease in AA.
The present invention relates to a composition for preventing, improving, or treating a disease related to bone loss caused by an osteoclast comprising an agastache rugosa extract, isoagastachoside included in the same, or a crude polysaccharide fraction as active ingredients. The present invention relates to a composition for inhibiting bone loss caused by an osteoclast comprising an agastache rugosa extract, isoagastachoside included in the same, or a crude polysaccharide fraction as active ingredients and a composition for inhibiting differentiation of an osteoclast progenitor to the osteoclast. The agastache rugosa extract, the isoagastachoside included in the same, or the crude polysaccharide fraction of the present invention can be manufactured by a plant which is grown in Korea to provide an advantage in terms of time and cost. The present invention is provided to increase bone density by effectively inhibiting differentiation, growth, or bone resorption functions of the osteoclast progenitor, thereby effectively preventing, improving, or treating the disease related to the bone loss caused by the differentiation to the osteoclast or excessive activity of the osteoclast. The present invention is safe with fewer side effects to a human body than chemical agents as a plant-derived natural material and independently inhibits the osteoclast progenitor from estrogen. Therefore, the present invention can be widely used for osteoporosis caused by various causes other than menopause.
The invention discloses a traditional Chinese medicine pill of a kidney-tonifying pill for replenishing essence, which is prepared from the following components in part by weight: prepared rhizome of rehmannia, desertliving cistanche, Chinese date peel, centipede, nidus vespae, ootheca Mantidis, lucid ganoderma, eucommia bark, cinnamon, dried ginger, ginseng, fructus amomi, tangerine and medlar, Chinese taxillus twig, longspur epimedium, Chinese dodder seed, fructus psoraleae, black peach pulp, pilose antler and other 19 traditional Chinese medicines are combined in a formula. 1. Has no influence or little influence on normal physiological functions and no toxic or side effect. 2. The effect is nonspecific and broad-spectrum. 3. Has the effects of regulating and tonifying kidney qi, invigorating kidney, tranquilizing mind, regulating and invigorating qi and blood, nourishing tendons, replenishing kidney essence, restoring kidney qi, tonifying the acquired body, strengthening the congenital body, invigorating yang, dredging yang channel, and treating sexual impotence. 4. Can improve symptom and sign of patients with kidney yang deficiency and kidney qi deficiency, invigorate spleen and tonify kidney, and radically cure impotence and strengthen body resistance and kidney.
PURPOSE: To obtain an immunomodulator useful for treating autoimmune diseases, rejection, allergic diseases, etc., by immobilizing a peptide capable of inducing the anergy in a T cell on a carrier insoluble in a humor. CONSTITUTION: This immunomodulator is obtained by immobilizing a peptide capable of inducing an antigenic nonreactional state (anergy) in a T cell on a carrier insoluble in a humor. The synthesis of the peptide capable of inducing the energy is simple in operations and preferably synthesized according to a solid-phase synthetic method. For example, blood, a lymph or an intraarticular fluid is cited as the humor. A carrier having a hydrophilic surface and reactive groups utilizable for forming covalent bonds between the carrier and the peptide such as amino group, carboxyl group or hydroxyl group is preferred as the carrier. The shape of the carrier is preferably granular or fibrous. Furthermore, the amount of the peptide immobilized on the carrier is preferably >=3×10<-8> mol/g (carrier), more preferably 1×10<-7> to 1×10<-4> mol/g (carrier).
Thyroid hormones play a crucial role in the development of the central nervous system and are considered pivotal to cognitive functions in the adult brain. Recently, thyroid dysfunction has been associated with Alzheimer's disease. The aim of this study was to assess the neuroprotective effects of triiodothyronine (T3) on insulin signaling, neuroinflammation, apoptosis, and cognitive function in a streptozotocin (STZ)-induced sporadic Alzheimer's disease-like model. Male Wistar rats underwent stereotaxic surgery for intracerebroventricular injections of streptozotocin (STZ; 2 mg/kg) or vehicle in the lateral ventricles to induce an AD-like model. The animals received a daily dose of 1.5 μg of T3/100 g body weight or the same volume of vehicle for 30 days and were subdivided into four experimental groups: (1) animals receiving citrate treated with saline (Control = CTL); (2) animals receiving citrate treated with T3 (T3); (3) animals receiving STZ treated with saline (STZ); and (4) animals receiving STZ treated with T3 (STZ + T3). The novel object recognition test was used to measure cognitive function. Serum analysis, real-time RT-PCR, immunohistochemistry, and immunoblotting analyses were also carried out. Our results demonstrated that T3 treatment reversed cognitive impairment and increased Akt and GSK3 phosphorylation in the treated group, while also reducing microglial activation (Iba-1) and GFAP expression (reactive astrocytes), along with TNF-α, IL-6, and IL-1β levels in the hippocampus. Additionally, T3 treatment increased levels of the anti-apoptotic protein Bcl-2 and reduced the expression of the pro-apoptotic protein BAX in the hippocampus. Our study demonstrated that T3 could potentially protect neurons in an AD model induced by STZ.
Obesity is a major global health concern because of its strong association with metabolic and neurodegenerative diseases such as diabetes, dementia, and Alzheimer's disease. Unfortunately, brain insulin resistance in obesity is likely to lead to neuroplasticity deficits. Since the evidence shows that insulin resistance in brain regions abundant in insulin receptors significantly alters mitochondrial efficiency and function, strategies targeting the mitochondrial quality control system may be of therapeutic and practical value in obesity-induced cognitive decline. Exercise is considered as a powerful stimulant of mitochondria that improves insulin sensitivity and enhances neuroplasticity. It has great potential as a non-pharmacological intervention against the onset and progression of obesity associated neurodegeneration. Here, we integrate the current knowledge of the mechanisms of neurodegenration in obesity and focus on brain insulin resistance to explain the relationship between the impairment of neuronal plasticity and mitochondrial dysfunction. This knowledge was synthesised to explore the exercise paradigm as a feasible intervention for obese neurodegenration in terms of improving brain insulin signals and regulating the mitochondrial quality control system.
This is an observational, retrospective, single centered study, using clinical data from the patient's medical record from the hospital, the national prescription database of the Directorate of Health, and the and ICD-10 codes from primary care records. For this analysis, medicines will be classified into drug classes based on the first five characters of their WHO Anatomical Therapeutic Chemical (ATC) code. The prevalence (pre) and incidence (post) of polypharmacy (≥5 or more regular medicines) and hyper-polypharmacy (≥10 regular medicines) will be calculated. Potentially inappropriate prescribing will be assessed in individuals ≥65 years applying Beers 2019, Start and Stopp 2014, explicit prescribing criteria. The analysis will be restricted to older individuals, as Beers criteria have not been validated in younger age groups. The anticholinergic burden will be assessed for all individuals ≥18 years will be assessed by applying the anticholinergic burden scale This stratification is important in order to deliver targeted interventions in resource-limited healthcare settings
The invention relates to the use of one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom for the prevention or treatment of infectious diseases caused by a hepatitis B virus which is resistant to nucleoside analogues or in the development or progression of which a hepatitis B virus resistant to nucleoside analogues plays a role. Furthermore, the invention relates to the use of one or more Phyllanthus component(s) or substances or mixture of substances obtained therefrom for the production of a pharmaceutical composition for the prevention or treatment of infectious diseases caused by a hepatitis B virus which is resistant to nucleoside analogues or in the development or progression of which a hepatitis B virus resistant to nucleoside analogues plays a role. Furthermore, the invention relates to the use of one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom for the inhibition of the amplification of a hepatitis B virus which is resistant to nucleoside analogues. Moreover, the invention relates to methods for the prevention or treatment of infectious diseases in a mammal caused by a hepatitis B virus which is resistant to nucleoside analogues or in the development or progression of which a hepatitis B virus resistant to nucleoside analogues plays a role, wherein one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom are administered to the mammal. Furthermore, the invention relates to methods for the inhibition of the amplification of a hepatitis B virus resistant to nucleoside analogues, wherein one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom are contacted with the viruses. In a preferred embodiment of the invention, the nucleoside analogues are selected from the group consisting of Lamivudine and Famciclovir.